People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Pharmaceuticals, Biotechnology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Metabolic Solutions Development Co Llc | — | Pharmaceuticals | Series B | $50.1M | $6.8M | 2009 |
| Cirius Therapeutics, Inc. | — | Biotechnology | Series B | $49.6M | $3.3M | 2024 |
| Tolera Therapeutics Inc | — | Biotechnology | Series A | $13.9M | $9.0M | 2010 |
| Intervention Insights, Inc. | — | Other Health Care | Series A | $6.4M | $84.0M | 2011 |
Mark Olesnavage at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark Olesnavage on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Zerbe | 2 | 5 |
| Gerald Callahan | 2 | 3 |
| Michael Jandernoa | 2 | 2 |
| Wright Steenrod | 1 | 9 |
| Michael Gross | 1 | 9 |
| John Kerschen | 1 | 5 |
| Donald Parfet | 1 | 5 |
| Robert Beardsley | 1 | 5 |
| Nilesh Kumar | 1 | 4 |
| Ashleigh Palmer | 1 | 4 |
| Robert A. Beardsley | 1 | 4 |
| Clynt Taylor | 1 | 3 |
| Suzette Dutch | 1 | 3 |
| Elaine Sun | 1 | 3 |
| Jim Schultz | 1 | 3 |
| Douglas Morton | 1 | 3 |
| Daniel Estes | 1 | 3 |
| Howard Dittrich | 1 | 2 |
| John Puisis | 1 | 2 |
| William Parfet | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.